Recession times is impacting everyone around the world by now and with the future expected to bring more suprises.
In uncertain times, it is interesting to see the increased popularity of LinkedIn. I am also amazed to see this becoming a sticky application where people are logging on regulary and updating their information as these updates in itself spells out a story.
I am excited about some of the new features including the ability to add applications such as the Poll, Research Surveys, Groups, etc. What's next?
Callum Bir
See my public profile
http://www.linkedin.com/in/callumbir
Friday, April 24, 2009
Saturday, January 3, 2009
Emerging trends in Electronic Data Capture :: Integration of EDC with eSource from EHR systems at sites
Aug, 2008. By Callum Bir
Increasingly clinical trials are coming under the regulatory lense because of lack of necessary accounting of the patient and drug effects information. The following article takes a look at the new trends in electronic data capture that help track the data better.
The adoption of electronic medical records (EMRs) in both hospitals and private practice is on a steady incline. Alongside the growth in EMR, Electronic Data Capture (EDC) systems are today used in an estimated 30-35% of clinical trials, again in both hospitals and private practices. The use of electronic data capture technologies provides the opportunity to significantly enhance clinical trial conduct through improved efficiency and accuracy, as well as the potential for real-time response to possible adverse situations. The data captured in clinical trial systems may be based upon a prior electronic source (eSource), such as EMR. Unfortunately, many of the EMR systems that manage the electronic source today cannot be used reliably for clinical research purposes because of the variability among these systems and the fact that they are not required to meet regulatory requirements for clinical trials. Therefore the data that are in the EMR system have to be printed or hand-transcribed and re-entered into the EDC system. The duplication of tasks, generation of paper and associated costs and inefficiencies, will only grow with the increasing use of electronic data sources. With the transformation in healthcare data collection migrating from a paper world to an EDC one, the scenario begs the question, "How can EDC integrate with these systems at sites and avoid redundant data collection?"
The eClinical Forum (www.eclinicalforum.com) and PhRMA EDC/eSource taskforce is very active in formulating standards around integrating aspects of clinical trial data with healthcare data. This article has reference to many of the survey work and visionary publications of these groups.
(Read more http://ehealthonline.org/articles/article-details.asp?Title=Emerging-trends-in-Electronic-Data-Capture&ArticalID=2071&Type=ZOOM%20IN )
Increasingly clinical trials are coming under the regulatory lense because of lack of necessary accounting of the patient and drug effects information. The following article takes a look at the new trends in electronic data capture that help track the data better.
The adoption of electronic medical records (EMRs) in both hospitals and private practice is on a steady incline. Alongside the growth in EMR, Electronic Data Capture (EDC) systems are today used in an estimated 30-35% of clinical trials, again in both hospitals and private practices. The use of electronic data capture technologies provides the opportunity to significantly enhance clinical trial conduct through improved efficiency and accuracy, as well as the potential for real-time response to possible adverse situations. The data captured in clinical trial systems may be based upon a prior electronic source (eSource), such as EMR. Unfortunately, many of the EMR systems that manage the electronic source today cannot be used reliably for clinical research purposes because of the variability among these systems and the fact that they are not required to meet regulatory requirements for clinical trials. Therefore the data that are in the EMR system have to be printed or hand-transcribed and re-entered into the EDC system. The duplication of tasks, generation of paper and associated costs and inefficiencies, will only grow with the increasing use of electronic data sources. With the transformation in healthcare data collection migrating from a paper world to an EDC one, the scenario begs the question, "How can EDC integrate with these systems at sites and avoid redundant data collection?"
The eClinical Forum (www.eclinicalforum.com) and PhRMA EDC/eSource taskforce is very active in formulating standards around integrating aspects of clinical trial data with healthcare data. This article has reference to many of the survey work and visionary publications of these groups.
(Read more http://ehealthonline.org/articles/article-details.asp?Title=Emerging-trends-in-Electronic-Data-Capture&ArticalID=2071&Type=ZOOM%20IN )
Clinical Trials the IT Way
Clinical trials often get delayed by as long as six months, and these delays can impact new product introduction and potentially hamper overall profitability. Each year, drug companies sponsor hundreds of clinical trials. While the cost of a new approved drug can easily exceed $800 million, the number of new drug approvals over the years does not commensurate with research and development (R&D) spending. Such declining R&D efficiency and expenditures could have been mitigated sooner through early termination of any trial that will eventually fail. Therefore, drug makers are determined to find new ways to improve their odds for success, including identifying potential “failures†earlier in the clinical trial process while maximizing opportunities for more promising drug candidates. In addition, research has also shown that significant costs savings could be achieved with shortened development cycles.
(Read More: http://www.pharmaasia.com/print.asp?id=7215)
(Read More: http://www.pharmaasia.com/print.asp?id=7215)
Translating Benchside Research into Bedside Reality
Research data from laboratories needs to be converted at a faster rate into clinical practice to diagnose and treat patients.
By Callum Bir, Director, Life Sciences, Oracle Asia Pacific .
The research and clinical care process has fundamentally changed in recent years. When it comes to drugs and therapeutic programs, one size no longer fits all and the traditional practice of reactive medicine with treatment selected by ‘trial and error’ will no longer suffice. Numerous factors have contributed to this phenomenon.The population is aging rapidly and Asia has been singled out as the world’s most rapidly aging region. By 2050, Asia is expected to house almost two-thirds of the world’s population over 60 years of age.
To exacerbate the situation, the number of chronic diseases such as heart attack, stroke, diabetes, respiratory disease and cancer has grown significantly. The World Health Organization (WHO) projects that by 2015, more than 70% of the people who will die from such diseases will be from Asia Pacific. This amounts to 270 million deaths out of 388 million deaths globally.In order to deliver effective treatment and high-quality care, the health sciences industry is beginning to recognize that research data from laboratories needs to be converted at a faster rate into clinical practice to diagnose and treat patients. The process of applying molecular insights from laboratory discovery to clinical care is known as translational medicine. This represents a paradigm shift in the biomedical research enterprise and is regarded as the future of healthcare.
(Read More) http://www.pharmaasia.com/article-6950-translatingbenchsideresearchintobedsidereality-Asia.html
Electronic Health Data Holds Potential to Hasten NDRs
Wednesday, September 10, 2008
Electronic Health Data Holds Potential to Hasten NDRs
EMR can help pharmaceutical companies reduce research costs and accelerate time to market for new drugs.
Callum Bir
The author is Director, Life Sciences, Global Industry Business Unit, Oracle Corporation, Asia Pacific and Japan
Electronic Medical Records (EMR), software that allows the creation, storage, editing and retrieval of a patient's data on a computer, and to a lesser extent Electronic/Personal Health Records (EHR/PHR) have been making strides around the world. Many hospitals or hospital clusters have to some extent either implemented EMRs or are in the process of doing so. Many countries around the region are also looking at putting in place the infrastructure that would support EHR/PHR as well. Countries like Singapore, Australia, Taiwan, Malaysia and Hong Kong have made significant progress in both these areas and there will be more to come.
As exciting, but often less reported, however, are the potential benefits such initiatives can deliver to the life sciences and biomedical industry. There are significant crossover benefits that take aim at some of the industry's most vexing challenges-more effective and efficient identification and recruitment of clinical trial participants and the ability to simultaneously capture clinical trial data from the electronic health record to decrease the costs of clinical trials, resulting in faster time-to-market for new drugs.
(Read More: http://biospectrumindia.ciol.com/content/BioTools/10809101.asp)Electronic Health Data Hold Potential to Transform Clinical Trial Recruitment and Hasten New Drug Releases
Initiatives at individual investigation sites in the US, Europe and Asia are revealing glimpses into the potential of patient's EMR data to transform clinical trial recruitment. Electronic Medical Records (EMRs) that allow the creation, storage, editing and retrieval of a patient's data on a computer and to a lesser extent electronic/ Personal Health Records (EHR/PHR) have been making strides around the world. Many hospitals or hospital clusters have to some extent either implemented EMRs or are in the process of doing so. Many countries in Asia Pacific are also looking at putting in place the infrastructure that would support EHR/PHR as well.... (Read More)
Subscribe to:
Posts (Atom)
